| Patient | Liliʻuokalani |
|---|---|
| Date of birth | 1947-09-02 |
| Identifiers | MRN HR-ET024-SYN; SSN (made up) 000-24-3086 |
| Document date | 2026-08-24 |
| Author | Kealani Morrison-Takeda, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-month review after the stroke. [S]
Liliʻuokalani returns six weeks after her annual wellness visit, five months after the stroke. She has had no new neurological symptoms, no bleeding and no falls, and has finished arranging a new song. She takes apixaban twice daily without missed doses and does the balance exercises from the community program twice a week. Her home blood pressure averages 122/72. Her hepatitis C antibody test was negative, and her bone density scan showed osteopenia (lowest T-score -2.1 at the femoral neck) with a ten-year risk of hip fracture below the level at which medicine is advised. She would like her zoster and Tdap vaccines today. [S]
| Element | Detail |
|---|---|
| Events | No recurrence, bleeding or falls |
| Home blood pressure | Average 122/72 mmHg |
| Screening results | Hepatitis C negative; osteopenia, below the treatment threshold |
| Function | Composing and playing daily |
| Cognition | MoCA 27 |
| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No weakness, numbness, speech, vision or balance problem |
| Hematologic | Negative | No nosebleeds, bruising, black stools or blood in the urine |
| Musculoskeletal | Negative | No falls |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily for 21 days, after a 325 mg loading dose in the emergency department | One tablet daily for 21 days | Oral route | 2026-03-16 to 2026-04-06 | completed | S |
| Clopidogrel 75 mg oral tablet, one tablet daily, after a 300 mg loading dose in the emergency department | One tablet daily | Oral route | 2026-03-16 to 2026-04-20 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Losartan 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Apixaban 5 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2026-04-20 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-24 | Body height | 160 | cm | S |
| 2026-08-24 | Body weight | 57.8 | kg | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-08-24 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-08-24 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-24 | Heart rate | 70 | /min | S |
| 2026-08-24 | Respiratory rate | 16 | /min | S |
| 2026-08-24 | Body temperature | 36.5 | Cel | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-24 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-24 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.88 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-08-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-24 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-24 | Hemoglobin [Mass/volume] in Blood | 12.7 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-08-24 | Platelets [#/volume] in Blood by Automated count | 226 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-24 | Cholesterol [Mass/volume] in Serum or Plasma | 134 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-08-24 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 62 | mg/dL | Goal below 70 mg/dL after ischemic stroke | Normal | S |
| 2026-08-24 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 57 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-08-24 | Triglyceride [Mass/volume] in Serum or Plasma | 90 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-24 | Total score [MoCA] | 27 | {score} | S |
Vital signs recorded on 2026-08-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/74, pulse 70 and regular; weight 57.8 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Neurological | Normal speech, strength, fine finger movements and gait |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Transient weakness and clumsiness of the right hand with word-finding difficulty, lasting about 20 minutes and fully resolved, the afternoon before the visit; suspected transient ischemic attack, ABCD2 score 5 (high risk); NIH Stroke Scale 0 | resolved | provisional | G45.9 | S — Synthetic presenting problem; resolved into the stroke diagnosis when diffusion MRI showed a small infarct at the stroke clinic the next day. Not a claim about her real symptoms. |
| Minor ischemic stroke: a small acute infarct in the cortex of the left precentral gyrus (left middle cerebral artery territory) on diffusion MRI, embolic in pattern, with full recovery (NIH Stroke Scale 0); source found to be paroxysmal atrial fibrillation; synthetic modern episode linked to her documented death from a stroke | active | confirmed | I63.412 | S — Synthetic modern diagnosis made at the stroke clinic the day after the visit; the 1917 cause of death remains D. |
| Hypertension: told of borderline readings in past years and not treated; 156/88 mmHg at intake | active | confirmed | I10 | S — Synthetic risk factor; no blood pressure from her lifetime is recorded in the cited sources. |
| Paroxysmal atrial fibrillation found on 30-day ambulatory monitoring after the stroke (six episodes, the longest 3 hours 10 minutes; burden about 3%); CHA2DS2-VASc 6, HAS-BLED 2 | active | confirmed | I48.0 | S — Synthetic finding on prolonged rhythm monitoring at five weeks. |
| Anterior nosebleed from the left side of the nasal septum four weeks after starting apixaban, stopped with pressure; hemoglobin unchanged; resolved | resolved | confirmed | R04.0 | S — Synthetic intercurrent problem at an unscheduled visit; a common minor bleed on an anticoagulant, not a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic and at home (target below 130/80 mmHg) and weight | Every visit | Completed today | 124/74 mmHg; home average 122/72; 57.8 kg |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | About two weeks after starting, then every six months | Completed today | Potassium 4.3 mmol/L, creatinine 0.88 mg/dL (eGFR 67) |
| Medication safety | Antithrombotic therapy and adherence | Every visit | Completed today | Apixaban twice daily, no missed doses; no bleeding |
| Laboratory | Anticoagulant safety: blood count, kidney function (creatinine clearance) and liver tests | Before starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her) | Completed today | Hemoglobin 12.7 g/dL, platelets 226; creatinine clearance about 48 mL/min; dose unchanged |
| Laboratory | Lipid panel (LDL goal below 70 mg/dL) | Four to twelve weeks after starting a statin, then every three to twelve months | Completed today | LDL 62 mg/dL, total cholesterol 134, HDL 57, triglycerides 90 |
| Survey | Cognitive screen (MoCA) | After the event, again within the first year, then periodically | Completed today | MoCA 27 within the first year after the stroke |
| Survey | Depression screen (PHQ-2, PHQ-9) | At the first post-stroke visit, then at least yearly | Up to date | PHQ-9 4 at three months; PHQ-2 0 at the wellness visit |
| Examination | Neurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptoms | With any change | Completed today | No new symptoms; examination normal |
| Imaging | ECG and prolonged rhythm monitoring for atrial fibrillation | ECG at baseline; at least 30 days of monitoring within six months of the event | Not indicated | Atrial fibrillation found and treated; no further monitoring needed |
| Examination | Falls risk | Every visit | Completed today | No falls; balance program twice a week |
| Self-management | Tobacco, alcohol and physical activity | Every visit | Completed today | Never smoker; alcohol rarely; walks daily |
| Self-management | Influenza vaccine | Yearly | Due | This season's high-dose vaccine in the autumn |
| Self-management | BE FAST and calling 911 | Every visit | Completed today | Reviewed |
| Self-management | Culturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic care | Every visit | Completed today | Her care continues as she directs, with her ʻohana and her own practices |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]
Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021); Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026); Signs and Symptoms of Stroke (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Age (2026)
Follow-up: Zoster dose 1 and Tdap given today; second zoster dose in two to six months. Influenza and COVID-19 vaccines in the autumn. Review in three months. Call 911 for any BE FAST sign. [S]